Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial

How will new US tariffs affect EU exports? Why did Apple’s profits soar despite tariff costs? What impact will Trump’s tariffs have on Canada? How is Amazon managing tariff-related cost pressures? Why is Microsoft’s market value hitting $4 trillion? How did Figma’s IPO triple its stock price? What’s behind Reddit’s surge in revenue and stock?

Nano-Cap Incannex's Sleep Apnea Candidate Shows Effectiveness And Safety In Mid-Stage Trial

benzinga.com/news/health-care/25/07/46722893/nano-cap-incannexs-sleep-apnea-candidate-shows-effectiveness-and-safety-in-mid-stage-trial

On Wednesday, Incannex Healthcare Inc. (NASDAQ:IXHL) released topline results from its RePOSA Phase 2 clinical trial evaluating IHL-42X, a novel oral drug candidate for obstructive sleep apnea (OSA), a condition affecting over 900 million people worldwide.
OSA is a common sleep disorder…

This story appeared on benzinga.com, 2025-07-30 14:10:30.